Chromadex (NASDAQ: CDXC) is one of 189 publicly-traded companies in the “Biotechnology & Medical Research” industry, but how does it weigh in compared to its competitors? We will compare Chromadex to related companies based on the strength of its profitability, risk, dividends, valuation, earnings, analyst recommendations and institutional ownership.
Institutional and Insider Ownership
6.1% of Chromadex shares are owned by institutional investors. Comparatively, 47.8% of shares of all “Biotechnology & Medical Research” companies are owned by institutional investors. 11.6% of Chromadex shares are owned by company insiders. Comparatively, 14.7% of shares of all “Biotechnology & Medical Research” companies are owned by company insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
This table compares Chromadex and its competitors’ net margins, return on equity and return on assets.
|Net Margins||Return on Equity||Return on Assets|
Volatility & Risk
Chromadex has a beta of 1.37, meaning that its stock price is 37% more volatile than the S&P 500. Comparatively, Chromadex’s competitors have a beta of 1.50, meaning that their average stock price is 50% more volatile than the S&P 500.
This is a summary of recent ratings and price targets for Chromadex and its competitors, as provided by MarketBeat.com.
|Sell Ratings||Hold Ratings||Buy Ratings||Strong Buy Ratings||Rating Score|
Chromadex presently has a consensus target price of $7.50, suggesting a potential upside of 21.36%. As a group, “Biotechnology & Medical Research” companies have a potential upside of 12.14%. Given Chromadex’s stronger consensus rating and higher probable upside, analysts plainly believe Chromadex is more favorable than its competitors.
Valuation and Earnings
This table compares Chromadex and its competitors revenue, earnings per share (EPS) and valuation.
|Gross Revenue||Net Income||Price/Earnings Ratio|
|Chromadex||$26.81 million||-$2.92 million||-44.14|
|Chromadex Competitors||$217.40 million||-$39.40 million||-64.23|
Chromadex’s competitors have higher revenue, but lower earnings than Chromadex. Chromadex is trading at a higher price-to-earnings ratio than its competitors, indicating that it is currently more expensive than other companies in its industry.
Chromadex beats its competitors on 7 of the 12 factors compared.
Chromadex Corporation and its subsidiaries ChromaDex, Inc., ChromaDex Analytics, Inc. and Spherix Consulting, Inc. provide research and quality-control products and services to the natural products industry. The Company allows its business units to discover, acquire, develop and commercialize ingredient technologies that address the dietary supplement, food, beverage, skin care and pharmaceutical markets. The Company operates through three segments: Ingredients, which develops, supplies and commercializes ingredient technologies; Core standards and contract services, which supplies phytochemical reference standards, which are small quantities of plant-based compounds used to research an array of attributes, reference materials and related contract services, and Scientific and regulatory consulting, which provides scientific and regulatory consulting to the clients in the food, supplement and pharmaceutical industries to manage health and regulatory risks.
Receive News & Ratings for Chromadex Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Chromadex and related companies with MarketBeat.com's FREE daily email newsletter.